Document is current
Any future updates will be listed below
-
Authors
Breukers, Sabine E. https://orcid.org/0009-0007-5667-1187
Crommelin, Robert D.
Smit, Laura A.
de Boer, Jan Paul
Navran, Arash
van Houdt, Winan J.
de Bree, Remco
Devriese, Lot A.
Haanen, John B. A. G.
Wondergem, Maurits
Zuur, Charlotte L.
Vogel, Wouter V. https://orcid.org/0000-0002-4992-8024
-
Funding
Funding for this research was provided by:
Bristol Myers Squibb Foundation (CA209-7W9)
Riki foundation
- License Information
-
More Information
Article History
Received: 6 February 2025
Accepted: 5 August 2025
First Online: 28 October 2025
Declarations
:
: This study was performed in line with the principles approval of the Declaration of Helsinki. Study protocol approval was granted by the Medical Ethics Committee of the Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital (METC-AVL) under file number NL72486 031 20 dated on 26th of June 2020.
: Written informed consent was obtained from all individual participants included in the study.
: The authors affirm that human research participants provided informed consent for publication of the images in Figs. d-e, d-e, and Supplementary Fig. .
: Charlotte L. Zuur reports receiving institutional research financial support from BMS to fund the present trial. Lot A. Devriese reports payments to my institution: speakers fee from Merck. John B.A.G. Haanen reports, all outside the submitted work: institutional honoraria for advisory roles for AIMM, Amgen, BioNTech, BMS, GSK, Ipsen, MSD, Merck Serono, Molecular Partners, Neogene Therapeutics, Novartis, Pfizer, Roche/Genentech, Sanofi, Seattle Genetics, Third Rock Ventures, Vaximm; stock option ownership of Neogene Therapeutics, Sastra Cell Therapy; Institutional research funding from Amgen, Asher Bio, BioNTech, BMS, MSD, Novartis Sastra Cell Therapy. The remaining authors declare no competing interests.
